Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Testosterone therapy and prostate cancer—safety concerns are well founded

Nature Reviews Urology volume 12, pages 48–54 (2015)Cite this article

Subjects

Abstract

Testosterone is a potent hormone with a variety of physiological effects. The diagnosis of androgen deficiency has increased dramatically over the past decade, along with the widespread use of testosterone supplementation therapy (TST). The long-term effects of TST are uncertain, and the risk of overdiagnosis and overtreatment of men who have a normal age-related decline in testosterone is substantial. The biology of the androgen receptor (AR) pathway is complex, and the saturation model does not take the heterogeneity of human prostate cancer into account. Large-scale trials to confirm the safety of testosterone with respect to the risks of prostate cancer and cardiovascular disease with reasonable confidence limits have not been done, and existing data are insufficient to exclude these adverse events. Instead, evidence suggests that prostate cancer could, in fact, be stimulated by TST, and that the risk of cardiovascular events is increased. Overall, TST seems to impose significant risks, and should be used with caution.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Davidson, C. Miracle. Esquire [online], (2012).

    Google Scholar 

  2. Thompson, I. M. Jr et al. Long-term survival of participants in the prostate cancer prevention trial. N. Engl. J. Med. 369, 603–610 (2013).

    Google Scholar 

  3. Andriole, G. L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192–1202 (2010).

    Google Scholar 

  4. Fleshner, N. E. et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 379, 1103–1111 (2012).

    Google Scholar 

  5. Kaufman, J. M. et al. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26, 833–876 (2005).

    Google Scholar 

  6. Zarotsky, V. et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology 2, 819–834 (2014).

    Google Scholar 

  7. Basaria, S. Male hypogonadism. Lancet 383, 1250–1263 (2014).

    Google Scholar 

  8. Wu, F. C. et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl. J. Med. 363, 123–135 (2010).

    Google Scholar 

  9. Handlesman, D. J. et al. Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse. Med. J. Aust. 199, 548–551 (2013).

    Google Scholar 

  10. Huggins, C. B., Stevens, R. B., & Hodges, C. V. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209 (1941).

    Google Scholar 

  11. Kawata, H. et al. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 70, 745–754 (2010).

    Google Scholar 

  12. Soto, A. M. & Sonnenschein, C. The two faces of Janus: sex steroids as mediators of both cell proliferation and cell death. J. Natl Cancer Inst. 93, 1673–1675 (2001).

    Google Scholar 

  13. Wang, Y. Z. & Wong, Y. C. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 35, 165–177 (1998).

    Google Scholar 

  14. van der Sluis, T. M. Serum testosterone enhances the metastatic ability of prostate cancer. World J. Urol. 31, 261–266 (2013).

    Google Scholar 

  15. Roddam, A. W., Allen, N. E., Appleby, P. & Key, T. J. Endogenous hormones and prostate cancer collaborative group. endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J. Natl Cancer Inst. 100, 170–183 (2008).

    Google Scholar 

  16. Salonia, A. et al. Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy. Clin. Cancer Res. 18, 3648–3657 (2012).

    Google Scholar 

  17. Curran, M. J. & Bihrle, W. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 53, 423–424 (1999).

    Google Scholar 

  18. Loughlin, K. R. & Richie, J. P. Prostate cancer after exogenous testosterone treatment for impotence. J. Urol. 157, 1845 (1997).

    Google Scholar 

  19. Rhoden, E. L. & Morgentaler, A. Risks of testosterone-replacement therapy and recommendations for monitoring. N. Engl. J. Med. 350, 482–492 (2004).

    Google Scholar 

  20. Calof, O. M. et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Gerontol. A. Biol. Sci. Med Sci. 60, 1451–1457 (2005).

    Google Scholar 

  21. Yamamoto, S. et al. Preoperative serum testosterone level as an independent predictorof treatment failure following radical prostatectomy. Eur. Urol. 52, 696–701 (2007).

    Google Scholar 

  22. Ribeiro M., Ruff, P. & Falkson, G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am. J. Clin. Oncol. 20, 605–608 (1997).

    Google Scholar 

  23. Sarosdy, M. F. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 109, 536–541 (2007).

    Google Scholar 

  24. Morales, A., Black, A. M. & Emerson, L. E. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int. 103, 62–64 (2009).

    Google Scholar 

  25. Agarwal, P. K. & Oefelein, M. G. Testosterone replacement therapy after primary treatment for prostate cancer. J. Urol. 173, 533–536 (2005).

    Google Scholar 

  26. Kaufman, J. M. & Graydon, R. J. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J. Urol. 172, 920–922 (2004).

    Google Scholar 

  27. Khera, M. et al. Testosterone replacement therapy following radical prostatectomy. J. Sex. Med. 6, 1165–1170 (2009).

    Google Scholar 

  28. Leibowitz, R. et al. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int. 105, 1397–1401 (2010).

    Google Scholar 

  29. Pastuszak, A. W. et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J. Urol. 190, 639–644 (2013).

    Google Scholar 

  30. Cui, Y., Zong, H., Yan, H. & Zhang, Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 17, 132–43 (2014).

    Google Scholar 

  31. Morgentaler, A. & Traish, A. M. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur. Urol. 55, 310–320 (2009).

    Google Scholar 

  32. Traish, A. M., Williams, D. F., Hoffman, N. D. & Wotan, H. H. Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates. Prog. Clin. Biol. Res. 262, 145–160 (1988).

    Google Scholar 

  33. Karantanos, T. et al. understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.09.049.

  34. Augello, M. A., Den, R. B. & Knudsen, K. E. AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev. 33, 399–411 (2014).

    Google Scholar 

  35. Daniels, G., Jha, R., Shen, Y., Logan, S. K. & Lee, P. Androgen receptor coactivators that inhibit prostate cancer growth. Am. J. Clin. Exp. Urol. 2, 62–70 (2014).

    Google Scholar 

  36. Foradori, C. D., Weiser, M. J. & Handa, R. J. Non-genomic actions of androgens. Front. Neuroendocrinol. 29, 169–168 (2008).

    Google Scholar 

  37. Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy Institute of Medicine of the National Academies (eds Liverman, C. T. & Blazer, D. G.) Testosterone and Aging: Clinical Research Directions (National Academies Press, 2003).

  38. Ajayi, A. A., Mathur, R. & Halushka, P. V. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 91, 2742–2747 (1995).

    Google Scholar 

  39. Abbate, R., Cioni, G., Ricci, I., Miranda, M. & Gori, A. M. Thrombosis and acute coronary syndrome. Thromb. Res. 129, 235–240 (2012).

    Google Scholar 

  40. Death, A. K. et al. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-kappaB-dependent pathway. Endocrinology 145, 1889–1897 (2004).

    Google Scholar 

  41. McCrohon, J. A., Jessup, W., Handelsman, D. J. & Celermajer, D. S. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 99, 2317–2322 (1999).

    Google Scholar 

  42. Pamukcu, B., Lip, G. Y., Devitt, A., Griffiths, H. & Shantsila, E. The role of monocytes in atherosclerotic coronary artery disease. Ann. Med. 42, 394–403 (2010).

    Google Scholar 

  43. Hoyos, C. M., Killick, R., Yee, B. J., Grunstein, R. R. & Liu, P. Y. Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnea: a randomized placebo-controlled trial. Clin. Endocrinol. (Oxf.) 77, 599–607 (2012).

    Google Scholar 

  44. Drager, L. F., Polotsky, V. Y. & Lorenzi-Filho, G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest 140, 534–542 (2011).

    Google Scholar 

  45. Lundh, B. & Gardner, F. H. The effect of testosterone in pharmacological doses on plasma volume and on some serum proteins in patients with sickle cell anemia and in sexually impotent men. Scand. J. Clin. Lab. Invest. 28, 72–78 (1971).

    Google Scholar 

  46. Johannsson, G., Gibney, J., Wolthers, T., Leung, K. C. & Ho, K. K. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J. Clin. Endocrinol. Metab. 90, 3989–3399 (2005).

    Google Scholar 

  47. Quan, A. et al. Androgens augment proximal tubule transport. Am. J. Physiol. Renal Physiol. 287, F452–F459 (2004).

    Google Scholar 

  48. D'Andrea, A. et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br. J. Sports Med. 41, 149–155 (2007).

    Google Scholar 

  49. Karila, T. A., Karjalainen, J. E., Mantysaari, M. J., Viitasalo, M. T. & Seppala, T. A. Anabolic androgenic steroids produce dose-dependent increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. Int. J. Sports Med. 24, 337–343 (2003).

    Google Scholar 

  50. Vigen, R. et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310, 1829–1836 (2013).

    Google Scholar 

  51. Silverman, E. A high stakes battle over testosterone. Wall Street Journal [online], (2014).

    Google Scholar 

  52. Finkle, W. D. et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 9, e85805 (2014).

    Google Scholar 

  53. Basaria, S. et al. Adverse events associated with testosterone administration. N. Engl. J. Med. 363, 109–122 (2010).

    Google Scholar 

  54. Haring, R. et al. Mendelian randomization suggests noncausal associations of testosterone with cardiometabolic risk factors and mortality. Andrology 1, 17–23 (2013).

    Google Scholar 

  55. Zhao, J. et al. Genetically predicted testosterone and cardiovascular risk factors in men: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study. Int. J. Epidemiol. 43, 140–148 (2014).

    Google Scholar 

  56. Xu L., Freeman, G., Cowling, B. J. & Schooling, C. M. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 11, 108 (2013).

    Google Scholar 

  57. Baillargeon, J. et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann. Pharmacother. 48, 1138–1144 (2014).

    Google Scholar 

  58. US Food and Drug Administration. FDA Drug Safety Communication: FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products [online], (2014).

  59. Health Canada. Summary Safety review—testosterone replacement products—cardiovascular risk [online], (2014).

  60. Grodstein F. et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335, 453–461 (1996).

    Google Scholar 

  61. Stampfer, M. J. & Colditz, G. A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20, 47–63 (1991).

    Google Scholar 

  62. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333 (2002).

    Google Scholar 

  63. Marjoribanks, J., Farquhar, C., Roberts, H. & Lethaby, A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews, Issue 7. Art. No.: CD004143. http://dx.doi.org/10.1002/14651858.CD004143.pub4.

  64. Folsom, A. R., Anderson, J. P. & Ross, J. A. Estrogen replacement therapy and ovarian cancer. Epidemiology 15, 100–104 (2004).

    Google Scholar 

  65. Fugh-Berman A. & Pearson, C. The overselling of hormone replacement therapy. Pharmacotherapy 22, 1205–1208 (2002).

    Google Scholar 

  66. Gurney, E. P., Nachtigall, M. J., Nachtigall, L. E. & Naftolin, F. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view. J. Steroid Biochem. Mol. Biol. 142, 4–11 (2014).

    Google Scholar 

  67. [No authors listed]. Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. The Copenhagen Study Group for Liver Diseases. Hepatology 11, 807–813 (1986).

  68. Snyder, P. J. et al. Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am. J. Med. 11, 255–260 (2001).

    Google Scholar 

  69. Emmelot-Vonk, M. H. et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 11, 39–52 (2008).

    Google Scholar 

  70. Legros, J. J. et al. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur. J. Endocrinol. 11, 821–831 (2009).

    Google Scholar 

  71. Srinivas-Shankar, U. et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 11, 639–650 (2010).

    Google Scholar 

  72. Jones, T. H. et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study) Diabetes Care 11, 828–837 (2011).

    Google Scholar 

  73. Ho, C. C. et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int. 11, 260–265 (2012).

    Google Scholar 

  74. Kaufman, J. M. et al. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J. Sex. Med. 11, 2079–2089 (2011).

    Google Scholar 

  75. Kalinchenko, S. Y. et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin. Endocrinol. (Oxf.) 11, 602–612 (2010).

    Google Scholar 

  76. Spitzer, M. et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann. Intern. Med. 157, 681–691 (2012).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, #MG 408, Toronto, M4N 3M5, ON, Canada

    Laurence Klotz

Authors
  1. Laurence Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurence Klotz.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klotz, L. Testosterone therapy and prostate cancer—safety concerns are well founded. Nat Rev Urol 12, 48–54 (2015). https://doi.org/10.1038/nrurol.2014.338

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2014.338

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer